Sign up to FoodBev and unlock more insights from the international food and beverage industry. Subscribers have access to webinars, newsletters, publications and more...
Are GLP-1 drugs a genuine long-term disruption or simply the latest health hype cycle? And with uptake rising fast, what does this mean for the future of F&B and how should the industry respond?
Maeva launches GLP-1-focused nutrition system for weight loss support
US direct-to-consumer metabolic wellness brand, Maeva, has launched a nutrition system designed to support individuals using GLP-1 weight-loss medications, as adoption of the drugs continues to rise.
GLP-1 drugs begin to reshape food demand, forcing F&B firms to rethink the basket
As appetite-suppressing GLP-1 medications gain traction, new research from Cornell University suggests measurable shifts in food purchasing are emerging.